D. E. Shaw & Co., Inc. Tcr2 Therapeutics Inc. Transaction History

D. E. Shaw & Co., Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.86 - $3.75 $787,509 - $1.59 Million	-423,392 Reduced 73.14%	155,495 $280,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $2.94 $471,838 - $657,442	-223,620 Reduced 27.87%	578,887 $1.68 Million
Q1 2022 May 16, 2022	BUY	$2.4 - $4.71 $861,000 - $1.69 Million	358,750 Added 80.84%	802,507 $2.22 Million
Q4 2021 Feb 14, 2022	BUY	$4.58 - $8.34 $2.03 Million - $3.7 Million	443,757 New	443,757 $2.07 Million
Q3 2021 Nov 15, 2021	SELL	$8.44 - $18.35 $467,154 - $1.02 Million	-55,350 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$16.41 - $24.71 $542,186 - $816,418	-33,040 Reduced 37.38%	55,350 $908,000
Q1 2021 May 17, 2021	BUY	$20.38 - $34.07 $1.8 Million - $3.01 Million	88,390 New	88,390 $1.95 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.